Literature DB >> 19734499

QTc: how long is too long?

J N Johnson1, M J Ackerman.   

Abstract

Congenital long QT syndrome (LQTS) affects an estimated 1 in 2500 people and typically presents with syncope, seizures or sudden death. Whereas someone exhibiting marked prolongation of the QT interval with QTc exceeding 500 ms who was just externally defibrillated from torsades de pointes while swimming poses negligible diagnostic challenge as to the unequivocal probability of LQTS, the certainty is considerably less for the otherwise asymptomatic person who happens to host a QTc value coined "borderline" (QTc > or = 440 ms). Although a normal QT interval imparts a much lower risk of life-threatening events, it does not preclude a patient from nevertheless harbouring a potentially lethal LQTS-causing genetic mutation. Indeed, genetic testing exerts significant diagnostic, prognostic and therapeutic implications. However, the 12-lead ECG remains the universal initial diagnostic test in the evaluation of LQTS and is subject to miscalculation, misinterpretation and mishandling. This review discusses the components of accurate QTc measurement and diagnosis, re-examines what is known about factors affecting QT interval measurement, and clarifies current recommendations regarding diagnosis of so-called "borderline" QT interval prolongation. The current guideline recommendations for the athlete with LQTS are also summarised.

Entities:  

Mesh:

Year:  2009        PMID: 19734499      PMCID: PMC3940069          DOI: 10.1136/bjsm.2008.054734

Source DB:  PubMed          Journal:  Br J Sports Med        ISSN: 0306-3674            Impact factor:   13.800


  48 in total

Review 1.  Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.

Authors:  Domenico Corrado; Antonio Pelliccia; Hans Halvor Bjørnstad; Luc Vanhees; Alessandro Biffi; Mats Borjesson; Nicole Panhuyzen-Goedkoop; Asterios Deligiannis; Erik Solberg; Dorian Dugmore; Klaus P Mellwig; Deodato Assanelli; Pietro Delise; Frank van-Buuren; Aris Anastasakis; Hein Heidbuchel; Ellen Hoffmann; Robert Fagard; Silvia G Priori; Cristina Basso; Eloisa Arbustini; Carina Blomstrom-Lundqvist; William J McKenna; Gaetano Thiene
Journal:  Eur Heart J       Date:  2005-02-02       Impact factor: 29.983

Review 2.  Task Force 7: arrhythmias.

Authors:  Douglas P Zipes; Michael J Ackerman; N A Mark Estes; Augustus O Grant; Robert J Myerburg; George Van Hare
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

3.  QT interval: how to measure it and what is "normal".

Authors:  Ilan Goldenberg; Arthur J Moss; Wojciech Zareba
Journal:  J Cardiovasc Electrophysiol       Date:  2006-03

4.  Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program.

Authors:  Domenico Corrado; Cristina Basso; Andrea Pavei; Pierantonio Michieli; Maurizio Schiavon; Gaetano Thiene
Journal:  JAMA       Date:  2006-10-04       Impact factor: 56.272

Review 5.  Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity.

Authors:  Carlo Napolitano; Raffaella Bloise; Silvia G Priori
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2006-04       Impact factor: 2.160

6.  Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome.

Authors:  Matteo Vatta; Michael J Ackerman; Bin Ye; Jonathan C Makielski; Enoh E Ughanze; Erica W Taylor; David J Tester; Ravi C Balijepalli; Jason D Foell; Zhaohui Li; Timothy J Kamp; Jeffrey A Towbin
Journal:  Circulation       Date:  2006-10-23       Impact factor: 29.690

7.  Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators.

Authors:  Hein Heidbüchel; Domenico Corrado; Allessandro Biffi; Ellen Hoffmann; Nicole Panhuyzen-Goedkoop; Jan Hoogsteen; Pietro Delise; Per Ivar Hoff; Antonio Pelliccia
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2006-10

8.  Cost-effectiveness of neonatal ECG screening for the long QT syndrome.

Authors:  Silvana Quaglini; Carla Rognoni; Carla Spazzolini; Silvia G Priori; Savina Mannarino; Peter J Schwartz
Journal:  Eur Heart J       Date:  2006-07-13       Impact factor: 29.983

9.  Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response.

Authors:  Himeshkumar Vyas; Joseph Hejlik; Michael J Ackerman
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

10.  Effect of clinical phenotype on yield of long QT syndrome genetic testing.

Authors:  David J Tester; Melissa L Will; Carla M Haglund; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

View more
  49 in total

1.  Comprehensive genetic testing can save lives in hereditary hearing loss.

Authors:  D Tekin; E Tutar; H Ozturkmen Akay; S Blanton; J Foster; M Tekin
Journal:  Clin Genet       Date:  2014-04-02       Impact factor: 4.438

2.  Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals.

Authors:  Ilan Goldenberg; Samuel Horr; Arthur J Moss; Coeli M Lopes; Alon Barsheshet; Scott McNitt; Wojciech Zareba; Mark L Andrews; Jennifer L Robinson; Emanuela H Locati; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Carlo Napolitano; Pyotr G Platonov; Silvia G Priori; Ming Qi; Peter J Schwartz; Wataru Shimizu; Jeffrey A Towbin; G Michael Vincent; Arthur A M Wilde; Li Zhang
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

3.  Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation.

Authors:  Julian Puppe; Deborah van Ooyen; Jeanne Neise; Fabinshy Thangarajah; Christian Eichler; Stefan Krämer; Roman Pfister; Peter Mallmann; Marina Wirtz; Guido Michels
Journal:  Breast Care (Basel)       Date:  2017-01-18       Impact factor: 2.860

Review 4.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

Review 5.  Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

Authors:  Geoffrey K Isbister; Colin B Page
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

Review 6.  Induced pluripotent stem cells as a disease modeling and drug screening platform.

Authors:  Antje D Ebert; Ping Liang; Joseph C Wu
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105

7.  Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy.

Authors:  Jonathan N Johnson; Camilla Grifoni; J Martijn Bos; Maha Saber-Ayad; Steve R Ommen; Stefano Nistri; Franco Cecchi; Iacopo Olivotto; Michael J Ackerman
Journal:  Eur Heart J       Date:  2011-02-22       Impact factor: 29.983

8.  Electrocardiographic QT interval and mortality: a meta-analysis.

Authors:  Yiyi Zhang; Wendy S Post; Elena Blasco-Colmenares; Darshan Dalal; Gordon F Tomaselli; Eliseo Guallar
Journal:  Epidemiology       Date:  2011-09       Impact factor: 4.822

9.  The ketogenic diet and the QT interval.

Authors:  Sivakumar Sudhakaran; Laila Yazdani; Kevin R Wheelan; Praveen K Rao
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-10-11

Review 10.  The Impending Dilemma of Electrocardiogram Screening in Athletic Children.

Authors:  Laure Léger; Boris Gojanovic; Nicole Sekarski; Erik J Meijboom; Yvan Mivelaz
Journal:  Pediatr Cardiol       Date:  2015-08-20       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.